Literature DB >> 2993542

Opiate- and alpha 2-adrenoceptor-induced hyperpolarizations of locus ceruleus neurons in brain slices: reversal by cyclic adenosine 3':5'-monophosphate analogues.

R Andrade, G K Aghajanian.   

Abstract

The purpose of this study was to investigate the ionic and second messenger mechanisms underlying the hyperpolarizations induced by the selective alpha 2-adrenoceptor agonist clonidine and the opiate agonist morphine in the locus ceruleus. Intracellular recordings were carried out in rat brain slices, and drugs at known concentrations were administered in the perfusate. The cyclic adenosine 3':5'-monophosphate (cAMP) analogues 8-bromo-cAMP and dibutyryl cAMP, while not altering basal activity, reversed the hyperpolarizations induced by clonidine or morphine. In contrast, administration of the parent compound adenosine failed to affect these responses. These results are consistent with previous biochemical studies suggesting that alpha 2-adrenergic and opiate agonists might signal their actions by reducing intracellular cAMP levels. Under manual voltage clamp, both clonidine and morphine elicited outward currents. The algebraic sum of the individual currents elicited by morphine and clonidine significantly exceeded the actual current elicited by their co-administration. This nonadditivity, as well as the observation that cAMP analogues reverse the morphine- and clonidine-induced hyperpolarizations, suggests that these compounds hyperpolarize locus ceruleus neurons through a shared ionic mechanism the activation of which might be signaled by a decrease in intracellular cAMP.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993542      PMCID: PMC6565318     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  23 in total

1.  Effect of chronic clonidine treatment on transmitter release from sympathetic varicosities of the guinea-pig vas deferens.

Authors:  D Knight; T C Cunnane; N A Lavidis
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

2.  The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy.

Authors:  L S Stone; L B MacMillan; K F Kitto; L E Limbird; G L Wilcox
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

3.  Multiple peptides converge to activate the same voltage-dependent current in a central pattern-generating circuit.

Authors:  A M Swensen; E Marder
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

4.  Presynaptic alpha 2-adrenoceptor, opioid kappa-receptor and adenosine A1-receptor interactions on noradrenaline release in rabbit brain cortex.

Authors:  N Limberger; L Späth; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

5.  Further characterization of the slow muscarinic responses in Xenopus oocytes.

Authors:  N Dascal; S Cohen
Journal:  Pflugers Arch       Date:  1987-08       Impact factor: 3.657

6.  Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors.

Authors:  Glenn D Andrews; Antonieta Lavin
Journal:  Neuropsychopharmacology       Date:  2006-03       Impact factor: 7.853

Review 7.  Flupirtine, a re-discovered drug, revisited.

Authors:  Istvan Szelenyi
Journal:  Inflamm Res       Date:  2013-01-16       Impact factor: 4.575

8.  Mechanism of mu-opioid receptor-mediated presynaptic inhibition in the rat hippocampus in vitro.

Authors:  M Capogna; B H Gähwiler; S M Thompson
Journal:  J Physiol       Date:  1993-10       Impact factor: 5.182

9.  Neuroplasticity regulation by noradrenaline in mammalian brain.

Authors:  Aude Marzo; Jing Bai; Satoru Otani
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

10.  Whole-cell recordings of inwardly rectifying K+ currents activated by 5-HT1A receptors on dorsal raphe neurones of the adult rat.

Authors:  N J Penington; J S Kelly; A P Fox
Journal:  J Physiol       Date:  1993-09       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.